Many liquid-based cancer screening and detection technologies focus on biochemical signals (such as conventional biomarkers), genomic signals (such as ct-DNAs) and CTCs (circulating tumor cells in the blood) and can typically only determine whether or not cancer has occurred at a static point in time.
Anpac Bio’s CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer, to determine future cancer risk, pinpoint where cancer is most likely located, and predict where in the body future risk is highest. All with an accessible, standard blood test, at a competitive price point.
Powered by our database of over 200,000 samples and cases, CDA is a new way to approach disease and cancer screening.
Our CDA device uses an integrated sensor system to detect several biophysical signals at the cellular, protein, and molecular levels, and our proprietary CDA algorithm synthesizes this data to generate a personalized risk assessment for each patient.
Innovators in the cancer screening market
CDA research ongoing since 2008.
Detects early signals of threatening cancer
And identifies the cancer’s location in the body with combination tests
Identifies the risks of 26 different types of cancer
With high sensitivity and specificity rates
Provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms
Resulting in accurate and easy-to-understand “CDA Values”.
Fully-operational, analyzing over 200,000 test samples ran to date
Identified pre- or early-stage cancers in patients previously diagnosed “cancer-free” through traditional methods.
CDA analyzes biophysical properties in the human blood
Research shows a correlation between biophysical properties (acoustical, electrical, magnetic, nano-mechanical and optical properties) and cancer occurrence.
Read the research Anpac Bio scientists presented at the American Society of Clinical Oncology (ASCO), the San Antonio Breast Cancer Symposium, and the Nobel Prize Laureate Summit on Biomedical Sciences.
Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.
Read the full article